Table 2 Mean time since last dose, and weighted proportion of anti-HBs seroprevalence by sex, age and type of vaccine at time of examination (N = 2,489)
Total included participants | Time since last dose (years, mean) | Anti-HBs level < 10 IU/L | Anti-HBs level 10–99 IU/L | Anti-HBs level ≥ 100 IU/L | ||||
|---|---|---|---|---|---|---|---|---|
n | n | % | n | % | n | % | ||
Total | 2,489 | 8.9 | 959 | 36 [34–39] | 900 | 36 [33–38] | 630 | 28 [26–30] |
Sex | ||||||||
Female | 1,263 | 9.1 | 527 | 40 [36–43] | 436 | 34 [30–37] | 300 | 27 [24–30] |
Male | 1,226 | 8.7 | 432 | 33 [30–37] | 464 | 38 [34–41] | 330 | 29 [26–33] |
Age | ||||||||
Age 3–6 | 525 | 3.6 | 89 | 15 [12–19] | 199 | 38 [32–43] | 237 | 47 [42–53] |
Age 7–10 | 613 | 7.3 | 223 | 38 [33–43] | 256 | 40 [35–45] | 134 | 22 [18–26] |
Age 11–13 | 619 | 10.5 | 313 | 48 [42–53] | 203 | 34 [28–39] | 103 | 19 [15–24] |
Age 14–17 | 732 | 12.6 | 334 | 46 [41–51] | 242 | 32 [27–37] | 156 | 22 [19–26] |
Type of vaccine | ||||||||
Monovalent | 588 | 11.8 | 243 | 42 [37–47] | 204 | 32.9 [28–38] | 141 | 25 [22–30] |
Polyvalenta: | 1,901 | 8.0 | 716 | 35 [32–37] | 696 | 37 [34–40] | 489 | 29 [26–31] |
Hexavac | 409 | 11.2 | 270 | 62 [55–68] | 111 | 31 [25–37] | 28 | 8 [5–13] |
Infanrix Hexa | 1,401 | 7.1 | 415 | 28 [25–31] | 564 | 39 [35–42] | 422 | 34 [31–37] |